2. Signaling Pathways
  3. Neuronal Signaling
  4. Cholinesterase (ChE)
  5. AChE Isoform
  6. AChE Inhibitor

AChE Inhibitor

AChE Inhibitors (378):

Cat. No. 상품명 효과 Purity
  • HY-N17425
    Lakoochin C
    		Inhibitor
    Lakoochin C is an inhibitor of acetylcholinesterase (AChE) (IC50 = 61.86 μM) and butyrylcholinesterase (BChE) (IC50 = 47.21 μM). Lakoochin C may be used in research related to Alzheimer's disease.
  • HY-49373
    AChE-IN-64
    		Inhibitor
    AChE-IN-64 (compound C4) is an AChE inhibitor (IC50: 36.9 µM), and can be used for cognitive disorders research.
  • HY-162681
    eeAChE-IN-3
    		Inhibitor
    eeAChE-IN-3 (compound YS3g) is an orally active, potent EeAChE and IL-6 inhibitor with IC50s of 0.54 μM, 0.49 μM, 8.54 μM and 0.57 μM for EeAChE, RatAChE, RatBuChE and IL-6, respectively. eeAChE-IN-3 improves STZ (HY-13753) (Streptozotocin; HY-13753)-induced learning and memory impairment in mice. eeAChE-IN-3 has the potential for Alzheimer's disease (AD) research.
  • HY-W856819
    Eseroline
    		Inhibitor
    Eseroline is a potent μ-opioid receptor agonist, which is the hydrolytic metabolite of Physostigmine (HY-N6608). Eseroline is a selective and competitive acetylcholinesterase (AChE) inhibitor, with its Ki values for AChE and BuChE being 0.1 μM and 200 μM respectively. Eseroline has nicotinic acetylcholine receptor allosteric enhancing ligand (nAChR-APL) activity, meaning it does not activate the receptor but significantly enhances the signal transduction of Ach triggered by the receptor. Eseroline is neurotoxic, causing cell membrane damage (LDH leakage) and energy metabolism collapse (ATP depletion). Eseroline can be used for the study of Alzheimer's disease.
  • HY-180358
    Gallamine
    		Inhibitor
    Gallamine is an allosteric, selective muscarinic M2 acetylcholine receptor antagonist (EC50: 130 nM for [3H]NMS dissociation from porcine muscarinic M2 receptors). Gallamine is also an acetylcholinesterase inhibitor (IC50s : 1070 μM, 1480 μM, 235  μM for EeAChE, hAChE, hBChE, respectively (in the absence of MeCN)). Gallamine increases free norepinephrine levels. Gallamine can be used as a muscle relaxant.
  • HY-161156
    BChE-IN-26
    		Inhibitor
    BChE-IN-26 (Compound 7b) is a selective AChE and BChE inhibitor with Ki value of 35 μM and 1.6 μM. BChE-IN-26 has cytotoxicity to human neuroblastoma (SH-SY5Y) cell line. BChE-IN-26 can be used for the research of Alzheimer’s disease.
  • HY-120131
    Cyanofenphos
    		Inhibitor
    Cyanofenphos is an orally active organophosphate insecticide and brain AChE inhibitor with neurotoxicity. Cyanofenphos induces delayed neurotoxicity such as ataxia and paralysis. Cyanofenphos also causes symptoms including somnolence, reduced feed intake and weight loss in hens. Cyanofenphos has a unique self-antagonistic effect: repeated low-dose pre-treatment not only reduces subsequent acute toxicity, but also exacerbates delayed neurotoxicity and attenuates enzyme inhibition, with the protective effect peaking at 24 h after the last pre-treatment. Cyanofenphos is commonly used in studies related to delayed neurotoxicity.
  • HY-162639
    α-Glucosidase-IN-68
    		Inhibitor
    α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC50 of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC50 of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models.
  • HY-W746884
    2-Methyl-2-butenyl (E)-Caffeate
    		Inhibitor
    2-Methyl-2-butenyl (E)-Caffeate is a type of caffeic acid ester compound. The petroleum ether and chloroform extracts containing 2-Methyl-2-butenyl (E)-Caffeate have inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The ether extract containing 2-Methyl-2-butenyl (E)-Caffeate exhibits strong antioxidant properties. 2-Methyl-2-butenyl (E)-Caffeate can be used in the research of Alzheimer's disease.
  • HY-150545
    AChE-IN-21
    		Inhibitor
    AChE-IN-21 (Compound I-8) is a potent, selective and orally active AChE inhibitor with an IC50 of 2.66 nM. AChE-IN-21 displays excellent BBB permeability in vitro.
  • HY-135427
    Quilostigmine
    		Inhibitor
    Quilostigmine (HP-290) is an orally active Physostigmine (HY-N6608) analogue, acetylcholinesterase (IC50: 148 nM for rat brain acetylcholinesterase) inhibitor. Quilostigmine has a long-lasting effect on tremors. Quetiapine can be used in the research of Alzheimer's disease.
  • HY-161842
    AChE-IN-67
    		Inhibitor
    AChE-IN-67 (compound 8n) is a potent AChE inhibitor, with an IC50 of 0.033 μM. AChE-IN-67 exhibits activity similar to Donepezil (HY-14566). AChE-IN-67 exhibits high blood-brain barrier (BBB) permeability. AChE-IN-67 can be used for Alzheimer's disease research.
  • HY-173152
    AChE/BChE-IN-26
    		Inhibitor
    AChE/BChE-IN-26 (Compound 20aa) is a cholinesterase inhibitor with IC50 values of 0.75 μM and 4.11 μM against eeAChE and eqBChE, respectively. AChE/BChE-IN-26 has antioxidant activity and can be used in the research of diseases such as Alzheimer's disease.
  • HY-170561
    AChE/BuChE-IN-6
    		Inhibitor
    AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg/mL, respectively. AChE/BuChE-IN-6 also exhibits strong DPPH free radical scavenging activity (IC50 = 3.15 μg/mL). In vivo toxicity studies indicate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical markers compared to the control group after long-term administration, and no abnormalities were observed in liver and kidney tissues. AChE/BuChE-IN-6 holds promise for research into Alzheimer's disease.
  • HY-165341
    SCR1693
    		Inhibitor
    SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC50 = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus.
  • HY-162606
    MAO-A/B-IN-3
    		Inhibitor
    MAO-A/B-IN-3 (Compound 12) stands out as a key dual MAO-AChE inhibitor, displaying excellent multi-target efficacy against MAO-A, MAO-B, and AChE with IC50 values of 67 nM, 29 nM, and 1370 nM respectively. MAO-A/B-IN-3 is adept at altering the A site (hydrophobic ring) and C site (semicarbazone chain) within ketone amine-based MTDLs to bolster the inhibitory potential against MAO-A/B while notably diminishing activity against AChE. MAO-A/B-IN-3 is poised for research applications in the field of neurodegenerative diseases.
  • HY-155822
    TZ3O
    		Inhibitor 98.17%
    TZ3O is an anticholinergic agent with neuroprotective effects. TZ3O inhibits acetylcholinesterase (AChE) activity in human plasma with an IC50 of 304.5 μM. TZ3O can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research.
  • HY-N19871
    Monogynol A
    		Inhibitor
    Monogynol A is an AChE/BChE inhibitor found in the aerial parts of Salvia trichoclada Bentham. Monogynol A can be used for the research of alzheimer’s disease.
  • HY-163126
    AChE-IN-52
    		Inhibitor
    AChE-IN-52 (compound A6) is an acetylcholinesterase (AChE) inhibitor. AChE-IN-52 shows antitumor efficacy, especially against breast cancer MCF-7 cells. AChE-IN-52 significantly disrupts the amino acid metabolism and inhibits migration of MCF-7. AChE-IN-52 plays anticancer role by regulating Best1 and HIST1H2BJ.
  • HY-152232
    BChE-IN-15
    		Inhibitor
    BChE-IN-15 (Compound 6) is a pseudo-irreversible and covalent BChE inhibitor with an IC50 of 1.76 nM against hBChE .